H.C. Wainwright analyst Patrick Trucchio initiated coverage of Invivyd with a Buy rating and $5 price target. The company’s "validated" antibody platform is positioned for success as COVID-19 transitions from pandemic to endemic, the analyst tells investors in a research note. Invivyd is a biopharmaceutical company focused on developing compounds to protect vulnerable people from the consequences of viral threats, beginning with SARS-CoV-2, says the firm.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IVVD:
- Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference
- Invivyd announces FDA has cleared IND application for VYD222
- Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update
- Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer
- Invivyd appoints Allen as CSO, Price as CTMO
